Promomed Group of Companies replenished its onco portfolio with a new drug for lung cancer therapy

Gefitinib-Promomed, used for the treatment of lung cancer, has received a registration certificate, becoming the third drug in the Promomed Group's cancer portfolio.

Non—small cell lung cancer (NSCLC) is by far the most common form of lung cancer, accounting for about 80% of all cases. Gefitinib-Promomed is a modern tyrosine kinase inhibitor used today as a drug in all lines of NSCLC therapy in patients with a mutation in the epidermal growth factor receptor (EGFR) gene.

The effectiveness of gefitinib has been studied in several large clinical trials. One of the first large-scale studies was the randomized study of INTEREST, in which the drug showed good tolerability, as well as a clinically significant improvement in the quality of life related to health in a larger number of patients. The results obtained confirm the safety and efficacy of the drug in patients with NSCLC.

Forming a portfolio of drugs aimed at treating socially significant diseases, including cancer, is one of the most important tasks for Promomed Group as part of its strategy to solve global medical problems, save lives and significantly improve patient health. When introducing new drugs to the market, including generic ones, the company offers patients effective and safe medicines due to the high quality of their substances, the manufacturability of production processes, and the highest quality control standards.

Gefitinib-Promomed will be available in the form of tablets with a dosage of 250 mg, which corresponds to standard application schemes.

Like most medicines produced by Promomed Group, this drug is included in the list of VED.